- Home
- OLP vs OMER Comparison
OLP vs OMER Comparison
Compare OLP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- OMER
- Stock Information
- Founded
- OLP 1982
- OMER 1994
- Country
- OLP United States
- OMER United States
- Employees
- OLP N/A
- OMER N/A
- Industry
- OLP Real Estate Investment Trusts
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- OMER Health Care
- Exchange
- OLP Nasdaq
- OMER Nasdaq
- Market Cap
- OLP N/A
- OMER 530.2M
- IPO Year
- OLP N/A
- OMER 2009
- Fundamental
- Price
- OLP $25.92
- OMER $9.21
- Analyst Decision
- OLP Strong Buy
- OMER Buy
- Analyst Count
- OLP 1
- OMER 4
- Target Price
- OLP $28.00
- OMER $22.50
- AVG Volume (30 Days)
- OLP 46.6K
- OMER 509.4K
- Earning Date
- OLP 03-04-2025
- OMER 03-31-2025
- Dividend Yield
- OLP 7.06%
- OMER N/A
- EPS Growth
- OLP 51.11
- OMER N/A
- EPS
- OLP 1.63
- OMER N/A
- Revenue
- OLP $89,142,000.00
- OMER N/A
- Revenue This Year
- OLP N/A
- OMER N/A
- Revenue Next Year
- OLP $4.71
- OMER N/A
- P/E Ratio
- OLP $15.65
- OMER N/A
- Revenue Growth
- OLP N/A
- OMER N/A
- 52 Week Low
- OLP $19.75
- OMER $2.61
- 52 Week High
- OLP $30.45
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- OLP 45.92
- OMER 49.57
- Support Level
- OLP $25.27
- OMER $8.28
- Resistance Level
- OLP $25.93
- OMER $9.08
- Average True Range (ATR)
- OLP 0.50
- OMER 0.55
- MACD
- OLP 0.12
- OMER -0.02
- Stochastic Oscillator
- OLP 71.79
- OMER 56.45
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.